13 results on '"F. Lee Tucker"'
Search Results
2. Can we improve breast cancer management using an image-guided histopathology workup supported by larger histopathology sections?
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, and András Vörös
- Subjects
Radiology, Nuclear Medicine and imaging ,General Medicine - Published
- 2023
3. The challenging imaging and histopathologic features of diffusely infiltrating breast cancer
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, Olga Puchkova, Renáta Bozó, Amy Ming-Fang Yen, Sam Li-Sheng Chen, Robert A. Smith, Stephen W. Duffy, and Tony Hsiu-Hsi Chen
- Subjects
Radiology, Nuclear Medicine and imaging ,General Medicine - Published
- 2023
4. A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, Amy Ming-Fang Yen, Sam Li-Sheng Chen, Grace Hsiao Hsuan Jen, Jackson Wei-Chun Wang, Robert A. Smith, Stephen W. Duffy, and Tony Hsiu-Hsi Chen
- Subjects
Humans ,Radiology, Nuclear Medicine and imaging ,Breast Neoplasms ,Female ,General Medicine ,Breast ,Prognosis ,Biomarkers ,Mammography - Abstract
To use mammographic tumour features (imaging biomarkers) to classify breast cancer according to its apparent anatomic site of origin in the new era where tumours are found at their nonpalpable, earliest detectable phase.Large format, subgross, three-dimensional histopathologic images of breast cancer subtypes and their corresponding imaging biomarkers were correlated with large format thin section histopathology and long-term patient outcome.This systematic correlation indicates that breast cancers arise from three separate fibroglandular tissue components: the terminal ductal lobular units (TDLUs), the major lactiferous ducts, and in the stem cells of the mesenchyme. The resulting three cancer subgroups have distinctly different clinical, histopathological and mammographic presentations and different long-term outcomes. The relative frequency of these three breast cancer subgroups is approximately 75%, 20% and 5%, respectively. Classification of breast cancers according to their anatomic site of origin, as demonstrated with breast imaging and confirmed by subgross histopathology, correlates closely with the long-term patient outcome.Classification of breast cancers according to their site of origin helps overcome the inconsistencies in the current histopathologic terminology with its ductal-lobular dichotomy. The ability of the imaging biomarkers to determine the site of tumour origin and serve as a prognostic indicator emphasizes the increasingly crucial role of breast imaging in the management of breast cancer. Basing breast cancer management upon anatomically relevant terminology challenges the conventional mindset. Our proposals are based on research results from an unprecedented number of prospectively collected nonpalpable breast cancers diagnosed at their earliest detectable phases and followed up for several decades. This article is a general introduction to a series of forthcoming articles describing in detail the breast malignancies originating from the three sites of origin.
- Published
- 2022
5. Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, Tony Hsiu-Hsi Chen, Robert A. Smith, Stephen W. Duffy, Sherry Yueh-Hsia Chiu, May Mei-Sheng Ku, Chiao-Yun Fan, and Amy Ming-Fang Yen
- Subjects
Carcinoma, Intraductal, Noninfiltrating ,Carcinoma, Ductal, Breast ,Calcinosis ,Humans ,Breast Neoplasms ,Female ,Radiology, Nuclear Medicine and imaging ,Breast ,General Medicine ,Biomarkers ,Mammography - Abstract
As we have previously demonstrated, breast cancers originating in the major lactiferous ducts and propagating through the process of neoductgenesis are a distinct subtype of invasive breast cancers, although by current practice they are placed within the group termed ductal carcinoma in situ (DCIS) and are consequently underdiagnosed and undertreated. Imaging biomarkers provide a reliable indication of the site of origin of this breast cancer subtype (Ductal Adenocarcinoma of the breast, DAB) and have excellent concordance with long-term patient outcome. In the present paper, the imaging biomarkers of DAB are described in detail to encourage and facilitate its recognition as a distinct, invasive breast cancer subtype.Correlation of breast imaging biomarkers with the corresponding histopathological findings using large format technology, with additional evidence from subgross, thick section histopathology to demonstrate the complex three-dimensional structure of the newly formed duct-like structures, neoducts.There are six imaging biomarkers (mammographic tumour features) of DAB. Four subgroups have characteristic malignant-type calcifications on the mammogram. Two of these are characterized by intraluminal necrosis producing fragmented or dotted casting type calcifications on the mammogram; another two subgroups are characterized by intraductal fluid production which may eventually calcify, producing skipping stone-like or string of pearl-like calcifications. A fifth DAB subgroup presents with bloody or serous nipple discharge and is usually occult on mammography but is detectable with galactography and magnetic resonance imaging (MRI). The sixth subgroup presents as architectural distortion on the mammogram without associated calcifications.Radiologists can use these well-defined imaging biomarkers to readily detect Ductal Adenocarcinoma of the Breast, DAB. Immunochemical biomarkers are generally not determined from the DAB itself, due to the erroneous assumption that DAB is non-invasive. MRI plays a crucial role in determining disease extent and guiding surgical management. The accumulating evidence that this disease subtype is, in fact, an invasive cancer, necessitates an urgent re-evaluation of the diagnostic and management criteria for this poorly understood malignancy.
- Published
- 2022
6. Breast cancers originating from the major lactiferous ducts and the process of neoductgenesis: Ductal Adenocarcinoma of the Breast, DAB
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, Amy Ming-Fang Yen, Rene Wei-Jung Chang, Chen-Yang Hsu, Robert A. Smith, Stephen W. Duffy, and Tony Hsiu-Hsi Chen
- Subjects
Carcinoma, Intraductal, Noninfiltrating ,Carcinoma, Ductal, Breast ,Humans ,Breast Neoplasms ,Female ,Radiology, Nuclear Medicine and imaging ,Breast ,General Medicine ,Prognosis ,Mammography - Abstract
To call attention to a highly fatal breast cancer subtype arising from the major lactiferous ducts that is currently underdiagnosed as ductal carcinoma in situ (DCIS) with or without microinvasion.All breast cancers diagnosed at the Department of Mammography, Falun Central Hospital, Sweden, since 1977 have been classified according to their mammographic tumour features (imaging biomarkers) and followed up at regular intervals for the past four decades. The imaging biomarkers characteristic of breast cancers apparently arising from the major lactiferous ducts have been correlated with large format thin and thick section histopathology and long-term patient outcome.Breast cancers arising within the major lactiferous ducts propagate intraductally and produce continuously branching neoducts through epithelial-mesenchymal transformation (EMT), an invasive process termed neoductgenesis, which eventually forms a massive tumour burden. The high fatality of this breast cancer subtype indicates its truly invasive nature, although it is conventionally termed ductal carcinoma in situ, DCIS, terminology which is at odds with its poor long-term patient outcome. The neoducts are filled with multiple layers of malignant cells, have no attached lobules, and propagate by forming multiple invasive side branches. These newly formed duct-like structures are surrounded by a desmoplastic reaction (cancer associated fibroblasts, CAFs) and periductal lymphocytic infiltration. The neoducts are tightly packed together in irregular formations bearing no resemblance to the paniculate branching structure of normal lactiferous ducts. Cancers originating from the major ducts have six imaging biomarkers which can be easily recognized at breast imaging. These are described in detail in an accompanying article.Neoductgenesis in the breast, DAB, is similar in appearance and prognosis to ductal adenocarcinoma of the prostate, DAP. We propose the term ductal adenocarcinoma of the breast, DAB, to facilitate its recognition as a distinct invasive breast cancer subtype. The high fatality rates associated with neoductgenesis reflect the failure of current histopathologic diagnostic criteria to effectively guide therapeutic practice. When the neoducts are associated with small stellate/spiculated or spherical/oval-shaped invasive cancers arising from the terminal ductal lobular units (TDLUs), the prognosis and management are erroneously estimated according to the smaller invasive tumour(s), giving a false sense of security often resulting in undertreatment. Recognition that neoductgenesis is an invasive malignancy is a prerequisite for preventing treatment failure.
- Published
- 2022
7. Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB
- Author
-
László Tabár, Peter B. Dean, F. Lee Tucker, Amy Ming-Fang Yen, Jean Ching-Yuan Fann, Abbie Ting-Yu Lin, Robert A. Smith, Stephen W. Duffy, and Tony Hsiu-Hsi Chen
- Subjects
Carcinoma, Lobular ,Carcinoma ,Carcinoma, Ductal, Breast ,Humans ,Breast Neoplasms ,Female ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Adenocarcinoma ,Biomarkers ,Mammography - Abstract
To use mammographic tumour features (imaging biomarkers) to identify and investigate breast cancers originating from the terminal ductal lobular units (TDLUs) of the breast in order to overcome the confusion arising from the current histopathology terminology, which calls cancers arising from the TDLUs either "ductal" or "lobular".Prospectively collected data from a randomized controlled mammography screening trial with more than four decades of follow up, and data from the subsequent population-based service screening program in Dalarna County, Sweden, provided the database necessary for studying nonpalpable, primarily screen-detected breast cancer cases in their earliest detectable phases. Large format thick (subgross) and thin section histopathologic images of breast cancers originating from the TDLUs were correlated with their mammographic tumour features (imaging biomarkers) and long-term patient outcome.This systematic correlation indicates that imaging biomarkers can reliably determine the site of origin of breast cancers arising from the terminal ductal lobular units (TDLUs). This breast cancer subgroup has four specific mammographic tumour features: the in situ carcinomas developing from the TDLUs appear as powdery or crushed stone-like calcifications, while the invasive carcinomas appear as stellate/spiculated or circular/oval shaped tumour masses. These features are easily identified with breast imaging, either alone or in combination, unifocal or multifocal. We propose calling breast cancers of TDLU origin acinar adenocarcinoma of the breast (AAB).The era of early detection necessitates rectifying the current, confusing histopathological nomenclature to one that is based on the anatomical site of origin of breast cancers. Invasive cancers originating from the TDLUs are either stellate/spiculated or circular, irrespective of the complex WHO histopathologic terminology. The mortality reduction accomplished by participation in mammography screening is mostly accomplished by identifying and treating the AABs in their non-palpable, early phase. AABs detected when 15 mm diameter with no associated carcinoma originating from the major lactiferous ducts (ductal adenocarcinoma of the breast, DAB) have a good to excellent long-term outcome, irrespective of the current terminology, which tends to lead to overtreatment of these early invasive tumours. The conventionally used prognostic factors, including immunohistochemical biomarkers, fail to identify those 1-14 mm invasive AABs tumours that are eventually fatal. This identification can be made preoperatively by including the characteristic mammographic tumour features, imaging biomarkers, in primary diagnosis, treatment planning, and predicting long-term patient outcome. Forthcoming articles will address breast malignancies originating from structures of the breast other than the TDLUs.
- Published
- 2022
8. Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes
- Author
-
Pamela M Otto, Erin I. Neuschler, Basak E. Dogan, A. Thomas Stavros, Reni Butler, Gisela L G Menezes, F Lee Tucker, Roger Aitchison, Stephen R. Grobmyer, and Philip T. Lavin
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Adolescent ,Breast Neoplasms ,Multimodal Imaging ,030218 nuclear medicine & medical imaging ,Correlation ,Diagnosis, Differential ,Photoacoustic Techniques ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Breast ,Young adult ,Aged ,Aged, 80 and over ,business.industry ,Cancer ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,030220 oncology & carcinogenesis ,Immunohistochemistry ,Female ,Ultrasonography, Mammary ,business ,Optoacoustic imaging - Abstract
Background Optoacoustic imaging can assess tumor hypoxia coregistered with US gray-scale images. The combination of optoacoustic imaging and US may have a role in distinguishing breast cancer molecular subtypes. Purpose To investigate whether optoacoustic US feature scores correlate with breast cancer molecular subtypes. Materials and Methods A total of 1972 women (with a total of 2055 breast masses) underwent prebiopsy optoacoustic US in a prospective multi-institutional study between December 2012 and September 2015. Seven readers blinded to pathologic diagnosis scored gray-scale US and optoacoustic US features of the known cancers. Optoacoustic US features within (internal) and outside of the tumor boundary (external) were scored. Immunohistochemistry findings were obtained from pathology reports. Multinomial logistic regression analysis was used to fit the US scores, adding optoacoustic US features to the model to investigate the incremental benefit of each feature. Kruskal-Wallis tests were used to analyze the relationship between molecular subtypes and feature scores. Results Among 653 invasive cancers identified in 629 women, a total of 532 cancers in 519 women, all of which had molecular markers available, were included in the analysis. Mean age ± standard deviation was 57.9 years ± 12.6. Mean total external optoacoustic US feature scores of luminal (A and B) breast cancers were higher (9.9 vs 8.8; P < .05) and total internal scores were lower (6.8 vs 7.7; P < .001) than those of triple-negative and human epidermal growth factor receptor 2-positive (HER2+) cancers. A multinomial logistic regression model showed that optoacoustic internal vessel (odds ratio [OR], 0.6; 95% confidence interval [CI]: 0.5, 0.8; P = .002), optoacoustic internal blush (OR, 0.7; 95% CI: 0.5, 0.9; P = .02), and optoacoustic internal hemoglobin (OR, 0.6; 95% CI: 0.5, 0.8; P = .001) were associated with classification of luminal versus triple-negative and HER2+ cancer subtypes. Conclusion Combined optoacoustic US imaging and gray-scale US features may help distinguish luminal breast cancers from triple-negative and human epidermal growth factor receptor 2-positive cancers. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Mann in this issue.
- Published
- 2019
9. Optoacoustic Breast Imaging: Imaging-Pathology Correlation of Optoacoustic Features in Benign and Malignant Breast Masses
- Author
-
Philip T. Lavin, Reni Butler, M. Böhm-Vélez, F Lee Tucker, Erini Makariou, Kenneth A Kist, Janine Katzen, Kathy Schilling, Lora D. Barke, Basak E. Dogan, Catherine A. Young, Stamatia Destounis, Erin I. Neuschler, and Stephen R. Grobmyer
- Subjects
Adult ,medicine.medical_specialty ,genetic structures ,Breast imaging ,Photoacoustic imaging in biomedicine ,Breast Neoplasms ,030218 nuclear medicine & medical imaging ,Photoacoustic Techniques ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Breast ultrasound ,medicine.diagnostic_test ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Image Enhancement ,030220 oncology & carcinogenesis ,Female ,Radiology ,Ultrasonography, Mammary ,business ,Optoacoustic imaging ,Ultrasound breast - Abstract
Optoacoustic ultrasound breast imaging is a fused anatomic and functional modality that shows morphologic features, as well as hemoglobin amount and relative oxygenation within and around breast masses. The purpose of this study is to investigate the positive predictive value (PPV) of optoacoustic ultrasound features in benign and malignant masses.In this study, 92 masses assessed as BI-RADS category 3, 4, or 5 in 94 subjects were imaged with optoacoustic ultrasound. Each mass was scored by seven blinded independent readers according to three internal features in the tumor interior and two external features in its boundary zone and periphery. Mean and median optoacoustic ultrasound scores were compared with histologic findings for biopsied masses and nonbiopsied BI-RADS category 3 masses, which were considered benign if they were stable at 12-month follow-up. Statistical significance was analyzed using a two-sided Wilcoxon rank sum test with a 0.05 significance level.Mean and median optoacoustic ultrasound scores for all individual internal and external features, as well as summed scores, were higher for malignant masses than for benign masses (p0.0001). High external scores, indicating increased hemoglobin and deoxygenation and abnormal vessel morphologic features in the tumor boundary zone and periphery, better distinguished benign from malignant masses than did high internal scores reflecting increased hemoglobin and deoxygenation within the tumor interior.High optoacoustic ultrasound scores, particularly those based on external features in the boundary zone and periphery of breast masses, have high PPVs for malignancy and, conversely, low optoacoustic ultrasound scores have low PPV for malignancy. The functional component of optoacoustic ultrasound may help to overcome some of the limitations of morphologic overlap in the distinction of benign and malignant masses.
- Published
- 2018
10. Downgrading and Upgrading Gray-Scale Ultrasound BI-RADS Categories of Benign and Malignant Masses With Optoacoustics: A Pilot Study
- Author
-
Erini Makariou, M. Böhm-Vélez, Erin I. Neuschler, F Lee Tucker, Basak E. Dogan, Lora D. Barke, Philip T. Lavin, Stephen R. Grobmyer, Reni Butler, Janine Katzen, Tchaiko M. Parris, Kenneth A Kist, Margaret L. Bertrand, Stamatia Destounis, and Catherine A. Young
- Subjects
Adult ,medicine.medical_specialty ,Breast imaging ,Photoacoustic imaging in biomedicine ,BI-RADS ,Breast Neoplasms ,Pilot Projects ,01 natural sciences ,Sensitivity and Specificity ,030218 nuclear medicine & medical imaging ,010309 optics ,Photoacoustic Techniques ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,0103 physical sciences ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,False Positive Reactions ,Prospective Studies ,skin and connective tissue diseases ,Breast ultrasound ,False Negative Reactions ,Aged ,medicine.diagnostic_test ,business.industry ,nutritional and metabolic diseases ,General Medicine ,Middle Aged ,medicine.disease ,Gray scale ultrasound ,Female ,Radiology ,Ultrasonography, Mammary ,Neoplasm Grading ,business ,Optoacoustic imaging - Abstract
False-positive findings remain challenging in breast imaging. This study investigates the incremental value of optoacoustic imaging in improving BI-RADS categorization of breast masses at ultrasound.The study device is an optoacoustic breast imaging device with a handheld duplex laser and internal gray-scale ultrasound probe, fusing functional and morphologic information (optoacoustic ultrasound). In this prospective multisite study, breast masses assessed as BI-RADS category 3, 4A, 4B, 4C, or 5 by site radiologists underwent both gray-scale ultrasound and optoacoustic imaging with the study device. Independent reader radiologists assessed internal gray-scale ultrasound and optoacoustic ultrasound features for each mass and assigned a BI-RADS category. The percentage of mass reads for which optoacoustic ultrasound resulted in a downgrade or upgrade of BI-RADS category relative to internal gray-scale ultrasound was determined.Of 94 total masses, 39 were biopsy-proven malignant, 44 were biopsy-proven benign, and 11 BI-RADS category 3 masses were stable at 12-month follow-up. The sensitivity of both optoacoustic ultrasound and internal gray-scale ultrasound was 97.1%. The specificity was 44.3% for optoacoustic ultrasound and 36.4% for internal gray-scale ultrasound. Using optoacoustic ultrasound, 41.7% of benign masses or BI-RADS category 3 masses that were stable at 12-month follow-up were downgraded to BI-RADS category 2 by independent readers; 36.6% of masses assigned BI-RADS category 4A were downgraded to BI-RADS category 3 or 2, and 10.1% assigned BI-RADS category 4B were downgraded to BI-RADS category 3 or 2. Using optoacoustic ultrasound, independent readers upgraded 75.0% of the malignant masses classified as category 4A, 4B, 4C, or 5, and 49.4% of the malignant masses were classified as category 4B, 4C, or 5.Optoacoustic ultrasound resulted in BI-RADS category downgrading of benign masses and upgrading of malignant masses compared with gray-scale ultrasound.
- Published
- 2018
11. A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists
- Author
-
Kenneth A Kist, Philip T. Lavin, Reni Butler, Tchaiko M. Parris, Lora D. Barke, Pamela Donlan, Stephen R. Grobmyer, Erin I. Neuschler, Janine Katzen, M. Böhm-Vélez, F Lee Tucker, Erini Makariou, Kathy Schilling, Margaret L. Bertrand, Stamatia Destounis, Catherine A. Young, and Basak E. Dogan
- Subjects
Adult ,medicine.medical_specialty ,Breast imaging ,Population ,Breast Neoplasms ,Malignancy ,01 natural sciences ,030218 nuclear medicine & medical imaging ,010309 optics ,Photoacoustic Techniques ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Positive predicative value ,0103 physical sciences ,Radiologists ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Breast ,Prospective Studies ,Prospective cohort study ,education ,Aged ,Aged, 80 and over ,Observer Variation ,education.field_of_study ,business.industry ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Image Enhancement ,Confidence interval ,United States ,Pre- and post-test probability ,Female ,Radiology ,Ultrasonography, Mammary ,business ,Optoacoustic imaging - Abstract
Purpose To compare the diagnostic utility of an investigational optoacoustic imaging device that fuses laser optical imaging (OA) with grayscale ultrasonography (US) to grayscale US alone in differentiating benign and malignant breast masses. Materials and Methods This prospective, 16-site study of 2105 women (study period: 12/21/2012 to 9/9/2015) compared Breast Imaging Reporting and Data System (BI-RADS) categories assigned by seven blinded independent readers to benign and malignant breast masses using OA/US versus US alone. BI-RADS 3, 4, or 5 masses assessed at diagnostic US with biopsy-proven histologic findings and BI-RADS 3 masses stable at 12 months were eligible. Independent readers reviewed US images obtained with the OA/US device, assigned a probability of malignancy (POM) and BI-RADS category, and locked results. The same independent readers then reviewed OA/US images, scored OA features, and assigned OA/US POM and a BI-RADS category. Specificity and sensitivity were calculated for US and OA/US. Benign and malignant mass upgrade and downgrade rates, positive and negative predictive values, and positive and negative likelihood ratios were compared. Results Of 2105 consented subjects with 2191 masses, 100 subjects (103 masses) were analyzed separately as a training population and excluded. An additional 202 subjects (210 masses) were excluded due to technical failures or incomplete imaging, 72 subjects (78 masses) due to protocol deviations, and 41 subjects (43 masses) due to high-risk histologic results. Of 1690 subjects with 1757 masses (1079 [61.4%] benign and 678 [38.6%] malignant masses), OA/US downgraded 40.8% (3078/7535) of benign mass reads, with a specificity of 43.0% (3242/7538, 99% confidence interval [CI]: 40.4%, 45.7%) for OA/US versus 28.1% (2120/7543, 99% CI: 25.8%, 30.5%) for the internal US of the OA/US device. OA/US exceeded US in specificity by 14.9% (P < .0001; 99% CI: 12.9, 16.9%). Sensitivity for biopsied malignant masses was 96.0% (4553/4745, 99% CI: 94.5%, 97.0%) for OA/US and 98.6% (4680/4746, 99% CI: 97.8%, 99.1%) for US (P < .0001). The negative likelihood ratio of 0.094 for OA/US indicates a negative examination can reduce a maximum US-assigned pretest probability of 17.8% (low BI-RADS 4B) to a posttest probability of 2% (BI-RADS 3). Conclusion OA/US increases the specificity of breast mass assessment compared with the device internal grayscale US alone. Online supplemental material is available for this article. © RSNA, 2017.
- Published
- 2017
12. New Era Pathologic Techniques in the Diagnosis and Reporting of Breast Cancers
- Author
-
F. Lee Tucker
- Subjects
medicine.medical_specialty ,Breast tissue ,Tumor size ,medicine.diagnostic_test ,business.industry ,Breast imaging ,Concordance ,medicine.disease ,Imaging data ,Breast cancer ,Oncology ,Biopsy ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,Stage (cooking) ,business - Abstract
The adoption of mammographic service screening has led to decreased mortality from breast cancer due primarily to the detection of smaller, earlier stage cancers. Advances in breast imaging technology have contributed significantly to the presurgical evaluation of women, including use of the image-guided biopsy and interdisciplinary pre-treatment planning. The presurgical imaging and final pathologic reporting of tumor characteristics are often discordant. Modern imaging techniques, including functional MRI and 3-D ultrasound provide a spatial depiction of breast cancer extent not reportable using conventional pathologic techniques dating from an era when a minority of breast cancers were screen-detected. By incorporating imaging data into a large-format pathologic evaluation of surgically resected breast tissue, it is possible to improve correlation of tumor size and extent, multifocality, and the evaluation of surgical margins. The importance of pathologic tumor characteristics in guiding therapy mandates optimization of imaging–pathologic correlation in this era of screen-detected breast cancer.
- Published
- 2008
13. 2090925 Opto-Acoustic (OA) Correlations With Histopathology For Suspicious Breast Masses
- Author
-
Philip T. Lavin, A. Thomas Stavros, and F Lee Tucker
- Subjects
Pathology ,medicine.medical_specialty ,Acoustics and Ultrasonics ,Radiological and Ultrasound Technology ,business.industry ,Biophysics ,Medicine ,Radiology, Nuclear Medicine and imaging ,Histopathology ,Radiology ,business - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.